sumi.news
Search
Following
Sign in
← Back to news
Markets
RSS Feed
sumi.news
Markets
Follow
Latest
Sat Jan 31
UBS Remains a Buy on British American Tobacco (BTI)
2d
Y
JPMorgan Raises PT on Shell plc (SHEL), Here’s Why
2d
Y
Oil Markets Face Iran Conflict With Little in Reserve
2d
Y
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next 5 Years, According to Wall Street Analysts
2d
Y
Is This 1 Number Nvidia's Biggest Risk?
2d
Y
401(k) Contribution Rates Explained: How Do You Compare to Other Savers
2d
Y
JPMorgan Lifts PT on Equinor ASA (EQNR) to NOK 240 From NOK 220
2d
Y
BofA Lifts PT on Kinross Gold Corporation (KGC) to $42.75 from $37.50, Here’s Why
2d
Y
Wells Fargo Lifts PT on Keurig Dr. Pepper Inc. (KDP) to $40 from $35 – Here’s Why
2d
Y
Vale S.A. (VALE) Gets Downgraded to Neutral from Buy by BofA, Here’s Why
2d
Y
Grupo Santander Downgrades BP p.l.c. (BP) to Neutral from Outperform
2d
Y
Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya
2d
Y
Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM
2d
Y
Why Eni S.p.A. (E) is One of the Best Cheap Stocks Under $50 to Buy Right Now
2d
Y
Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 – Here’s Why
2d
Y
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why
2d
Y
Is Halozyme Therapeutics (HALO) a Buy Post Earnings?
2d
Y
Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025
2d
Y
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results
2d
Y
Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45
2d
Y
Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31
2d
Y
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here’s Why
2d
Y
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025
2d
Y
Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114 – Here’s Why
2d
Y
Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 – Here’s Why
2d
Y
Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now?
2d
Y
Is the Trump Bull Market on Its Last Leg? 4 Historically Accurate Indicators Offer a Clear Answer.
2d
Y
Analyst Sentiment on SS&C Technologies (SSNC) Remains Strong Despite Lingering AI Risks
2d
Y
Truist Analysts Mixed on EPAM Systems (EPAM) Despite Revenue, Operating Income Beat
2d
Y
Jefferies Bullish on ICON (ICLR) Despite Share Price Decline
2d
Y
Leidos Holdings (LDOS) Advances Operations as Terminal Flight Data Manager System Goes Live At Reagan National Airport
2d
Y
Cascades Q4 Earnings Call Highlights
2d
Y
CCL Industries Q4 Earnings Call Highlights
2d
Y
BTB Real Estate Investment Trust Q4 Earnings Call Highlights
2d
Y
Boralex Q4 Earnings Call Highlights
2d
Y
Black Diamond Group Q4 Earnings Call Highlights
2d
Y
Amerigo Resources Q4 Earnings Call Highlights
2d
Y
Barclays Lowers PT on ACV Auctions (ACVA)
2d
Y
Morgan Stanley Lowers PT on Playtika Holding (PLTK)
2d
Y
Clover Health Investments (CLOV) Posts Q4 2025 Earnings
2d
Y
N-able (NABL) Expands Anomaly Detection Capabilities For Cove Data
2d
Y
MiMedx Group (MDXG) Delivers Record Full Year Revenue
2d
Y
Optimum Communications (OPTU) Misses Q4 2025 EPS Estimates
2d
Y
Gogo Inc. (GOGO) Posts FQ4 2025 Earnings, Here’s What You Need to Know
2d
Y
B. Riley Lowers PT on AMC Entertainment Holdings (AMC), Here’s Why
2d
Y
Payoneer Global (PAYO) Crosses $1 Billion in Annual Revenue
2d
Y
Why There Are Better Alternatives Than Welltower In 2026
2d
S
Apple Hospitality REIT: A High-Yield Monthly Dividend Stock That's Still Undervalued
2d
S
Permian Resources: A Rollup Strategy Continues The Growth Story
2d
S
ADX + SCHD: The Ultimate Barbell Strategy To Navigate The 2026 AI Uncertainty
2d
S
More →